Top Markets
Coin of the day
Accelerate Diagnostics, Inc. Accelerate Diagnostics, Inc.

Accelerate Diagnostics, Inc.

AXDX
Rank in Stocks #40437
Accelerate Diagnostics, Inc. is an in vitro diagnostics company specializing in... Accelerate Diagnostics, Inc. is an in vitro diagnostics company specializing in solutions for the rapid diagnosis of critical infections, with operations spanning the United States, Europe, and the Middle East. The company's primary offering is the Accelerate Pheno system, an advanced in vitro diagnostic platform. Paired with its dedicated test kit, the Accelerate PhenoTest, this system facilitates quick identification and antimicrobial susceptibility testing (AST) for pathogens responsible for severe or healthcare-associated infections, encompassing both Gram-positive and Gram-negative organisms. The PhenoTest is specifically designed to yield crucial ID and AST results for patients suspected of bacteremia or fungemia – life-threatening conditions marked by high morbidity and mortality risks. Established in 1982, the company initially operated as Accelr8 Technology Corporation before adopting its current name, Accelerate Diagnostics, Inc., in December 2012. Its corporate headquarters are located in Tucson, Arizona.
Share Price
$0.01005
Last synced: 2025-06-09
Market Cap
$146.42K
Change (1 day)
-28.21%
Change (1 year)
0.00%
Country
US
Trade Accelerate Diagnostics, Inc. (AXDX)

Category

Earnings for Accelerate Diagnostics, Inc. (AXDX)
Earnings in 2026 TTM: 0
According to Accelerate Diagnostics, Inc. latest financial reports the company's current earnings are 0. In 2026 the company made an earning of 0, equal to its 2026 earnings that were of 0. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Accelerate Diagnostics, Inc. from 2026 to 2026
Earnings at the end of each year
Year Earnings Change
Not enough data for the provided dates.
Earnings for similar companies or competitors
Company Earnings Earnings Difference Country
$7.51B -
US
$5.15B -
US
$5.56B -
IE
$3.86B -
US
$1.42B -
US